Missed Period Pill Study (NCT04940013) | Clinical Trial Compass
TerminatedPhase 4
Missed Period Pill Study
Stopped: Lack of successful recruitment and loss of funding
United States17 participantsStarted 2021-10-25
Plain-language summary
The Missed Period Pill Study is a prospective observational study among people who decide to use misoprostol alone for menstrual regulation.
Who can participate
Age range18 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Be 18 years old or older
* Read and speak English
* Know the date of their last menstrual period within 2 days
* Have a period that is late by up to 14 days
* Have had regular periods in the last 4-6 months
* Does not want to be pregnant; understand that if they are pregnant, the pills will end their pregnancy
* Be willing to have an abortion if the missed period pill does not work, and informed of potential for birth defects in any ongoing pregnancy
* Does not want to verify pregnancy status
* Does not have risk factors for ectopic pregnancy (history of ectopic pregnancy, recent vaginal bleeding or spotting, pelvic pain on one side, prior permanent contraception, or other tubal surgery)
* Does not have an IUD
* Does not currently use a contraceptive implant or injectable
* Does not have contraindications to misoprostol
* Agree to participate in the follow up visit/call
Exclusion Criteria:
* Participants who have contraindications to misoprostol
* Unknown date of last menstrual period
* Risk factors for ectopic pregnancy (history of ectopic pregnancy, recent vaginal bleeding or spotting, pelvic pain on one side, prior permanent contraception, or other tubal surgery)
* Irregular menses or any other condition that in the opinion of the Principal Investigator would compromise participant safety.
What they're measuring
1
Interest in missed period pills
Timeframe: Documented at Enrollment Survey
2
Satisfaction with missed period pills
Timeframe: Documented at Follow-up Survey, 4 weeks after drug administration